Mesenchymal stromal cells improve early lymphocyte recovery and T cell reconstitution after autologous hematopoietic stem cell transplantation in patients with malignant lymphomas

Batorov, E. V.; Shevela, Е. Ya.; Тихонова, М. А.; Batorova, Dariya S.; Ushakova, G. Yu.; Sizikova, S. A.; Sergeevicheva, V. V.; Gilevich, Andrey V.; Kryuchkova, I. V.; Останин, А. А.; Черных, Е. Р.

doi:10.1016/j.cellimm.2015.07.001

Cited by 20 publications

(15 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gentamicin is a broad-spectrum antibiotic used to preserve the aseptic culture of cells (21)(22)(23). In the present study, it was demonstrated that the CIK activity was significant inhibited by gentamicin, and further research revealed that a protein P43 was associated with CIK activity.…”

Section: Discussionmentioning

confidence: 56%

Identification of a protein associated with the activity of cytokine‑induced killer cells

et al. 2017

View full text Add to dashboard Cite

Abstract. Cytokine-induced killer cells (CIKs) adoptive immunotherapy for efficient antitumor ability is used clinically, but details regarding the proteins associated with CIK activity remain unclear. In the current study, the cytotoxicity of CIKs on hepatoma was identified to be significantly downregulated by 1.61-fold following gentamincin treatment. Further research revealed that a differentially expressed protein (P43) was significantly downregulated by 1.22-fold using one-dimensional gel electrophoresis analysis. Of these, the P43 was identified as human haptoglobin using liquid chromatography-mass spectrometry. Western blotting demonstrated that the haptoglobin specifically reacted with rabbit anti-human-haptoglobin. Furthermore, western blotting results verified that the haptoglobin was significantly downregulated by 1.17-fold compared with the control group. In addition, the expression of haptoglobin mRNA was significantly downregulated by 1.73-fold following gentamincin treatment. Taken together, the results of the present study demonstrated that the expression of haptoglobin protein was associated with the activity of CIKs, and the results will be beneficial to the further investigation of CIK activity-enhancement mechanism.

show abstract

Section: Discussionmentioning

confidence: 56%

Identification of a protein associated with the activity of cytokine‑induced killer cells

et al. 2017

View full text Add to dashboard Cite

show abstract

“…49 Mesenchymal stem cells have also been shown to promote early immune reconstitution for lymphomas after ASCT. 50 To our knowledge, this is the second systematic review but the first meta-analysis comparing bone marrow versus peripheral blood ASCT in patients with lymphoma with a focus on survival and relapse. The previous systematic review only included RCTs and focused on engraftment.…”

Section: Discussionmentioning

confidence: 99%

Untitled

Jiang

Yue²,

Xu³

et al. 2018

Exp Clin Transplant

View full text Add to dashboard Cite

Objectives: The choice of whether to use bone marrow or peripheral blood in autologous transplantation remains controversial. Posttransplant relapse and long-term survival are critical issues. Materials and Methods: Studies that compared bone marrow transplant versus peripheral blood stem cell transplant in lymphoma patients were searched. Our search resulted in 15 studies. Results: Pooled data showed contradictory results with no conclusive differences in overall survival (for randomized controlled trials vs nonrandomized controlled trials: hazard ratio = 0.69 vs 1.17; 95% confidence interval, 0.44-1.10 vs 0.90-1.51; and P = .12 vs P = .25), progression-free survival (for randomized controlled trials vs nonrandomized controlled trials: hazard ratio = 0.89 vs 1.14; 95% confidence interval, 0.57-1.38 vs 0.82-1.58; and P = .60 vs P = .43), and relapse rates. However, we observed an overall trend toward lower relapse rate after bone marrow transplant. Lower relapse rate was likely associated with better progression-free survival (P = .052), and lower transplant-related mortality was associated with better overall survival (P = .043). Conclusions: Autologous bone marrow transplant with mobilization should be reconsidered for lymphoma patients to reduce recurrence and improve quality of life. More powered randomized controlled trials are warranted to update our findings. Key words: Autologous transplantation, Bone marrow transplant, Hematopoietic stem cells IntroductionHigh-dose chemotherapy followed by autologous hematopoietic stem cell transplant (auto-HSCT or ASCT) has been a standard treatment modality for refractory or relapsed non-Hodgkin lymphoma (NHL) and Hodgkin disease. Early consolidative transplant improves the prognosis of patients with high-risk aggressive lymphoma who gain little benefit from conventional regimens alone. Autologous bone marrow and peripheral blood progenitor cells permit the use of significantly intensified chemotherapy or radiotherapy irrespective of fatal myelosuppression or hematologic toxicity. As a first-line treatment, high-dose chemotherapy plus ASCT substantially reduces the bone marrow tumor load, resulting in a high rate of complete response, but late relapses are common. Bone marrow transplant (BMT), which contains a number of different stem cell populations, including hematopoietic stem cells, mesenchymal stem cells, endothelial progenitor cells, and fibroblasts, may have a protective effect. Peripheral blood progenitor cells have become more popular due to their faster trilineage engraftment or because NHL usually involves the bone marrow. However, whether bone marrow or mobilized peripheral blood has more tumor cell contamination or greater clonogenic potential is unclear because tumor cells can also be mobilized to the peripheral blood. Although "solid tumors" like lymphoma are distinct from leukemia or other blood cancers, most systematic reviews and meta-analyses on this topic have taken all hematologic malignancies into account. To further investigate whether ...

show abstract

“…In clinical practice, MSCs are co-infused with allogeneic HSCs to promote hematological engraftment and prevent engraftment failure and poor graft function [41,44,45]. Published data demonstrate that MSCs may reduce the risk of graft failure by modulating host alloreactivity and/or by promoting a better engraftment of donor hematopoiesis in HLA haploidentical allograft transplantation [41,46,47,48,49]. In UCB transplantation, the co-infusion of MSCs with UCBsc promotes hematopoietic engraftment [50,51] and may have a favorable effect on GvHD prevention [45].…”

Section: Clinical Applications Of Mscs In Allo-hsct and Gvhdmentioning

confidence: 99%

Mesenchymal Stem Cell Derived Extracellular Vesicles: A Role in Hematopoietic Transplantation?

Luca

Trino

Laurenzana

et al. 2017

IJMS

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are a heterogeneous cellular population containing different progenitors able to repair tissues, support hematopoiesis, and modulate immune and inflammatory responses. Several clinical trials have used MSCs in allogeneic hematopoietic stem cell transplantation (allo-HSCT) to prevent hematopoietic stem cell (HSC) engraftment failure, reduce aplasia post chemotherapy, and to control graft versus host disease (GvHD). The efficacy of MSCs is linked to their immune suppressive and anti-inflammatory properties primarily due to the release of soluble factors. Recent studies indicate that most of these effects are mediated by extracellular vesicles (EVs). MSC-EVs have therefore therapeutic effects in regenerative medicine, tumor inhibition, and immune-regulation. MSC-EVs may offer specific advantages for patient safety, such as lower propensity to trigger innate and adaptive immune responses. It has been also shown that MSC-EVs can prevent or treat acute-GvHD by modulating the immune-response and, combined with HSCs, may contribute to the hematopoietic microenvironment reconstitution. Finally, MSC-EVs may provide a new potential therapeutic option (e.g., transplantation, gene therapy) for different diseases, particularly hematological malignancies. In this review, we will describe MSC and MSC-EVs role in improving allo-HSCT procedures and in treating GvHD.

show abstract

Mesenchymal stromal cells improve early lymphocyte recovery and T cell reconstitution after autologous hematopoietic stem cell transplantation in patients with malignant lymphomas

Cited by 20 publications

References 32 publications

Identification of a protein associated with the activity of cytokine‑induced killer cells

Identification of a protein associated with the activity of cytokine‑induced killer cells

Untitled

Mesenchymal Stem Cell Derived Extracellular Vesicles: A Role in Hematopoietic Transplantation?

Contact Info

Product

Resources

About